Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 5/20 | 0.34 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 2/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3706397 | 0.79 | LATS1 (0.36) | LATS1LATS2APPPDE5APDE4A | |
| SCHEMBL12209227 | 0.73 | ADORA2A (0.40) | LATS1LATS2KMT2AHTTPDE4A | |
| SCHEMBL3713429 | 0.71 | XDH (0.37) | KMT2AAPPPDE5APDE4APDE4B | |
| SCHEMBL3708672 | 0.71 | PDE4A (0.44) | APPPDE5AHTTJAK2PDE4A | |
| SCHEMBL1709800 | 0.70 | IRAK4 (0.49) | KMT2AJAK2 | |
| SCHEMBL3705307 | 0.68 | MBOAT4 (0.37) | APPPDE5AJAK2PDE4APDE4B | |
| SCHEMBL3715489 | 0.68 | SYK (0.41) | KMT2AAPPPDE5AHTTPDE4A | |
| SCHEMBL3712626 | 0.68 | IRAK4 (0.44) | KMT2APDE5AJAK2PDE4A | |
| SCHEMBL3711032 | 0.68 | ESR1 (0.45) | LATS1LATS2APPPDE5AHTT | |
| SCHEMBL1709887 | 0.68 | SYK (0.51) | KMT2AAPPPDE5AJAK2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | CDK2, DPYD, CDK3 | LATS1 635/4885LATS2 783/4885KMT2A 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.